The Assay Podcast brings you inside the conversations shaping the mining and investment market. Hear from CEOs, investors and sector leaders through company updates, executive interviews and live ...

Catheter-associated urinary tract infections (CAUTIs) are one of the most common hospital-associated infections in the United States, accounting for >1 million cases annually. One CAUTI pathogen, ...

Potency assays are essential for product quality and patient safety. These tests enable a direct measurement of a biologic's functional activity, verifying that the therapy works as intended. Potency ...

Inspired by how a car uses an engine and a steering wheel to reach its destination, the nanorobot integrates two enzymatic functions. Urease works for propulsion by harnessing endogenous urea in ...

Lateral flow assays (LFAs) have become indispensable tools in diagnostics valued for their speed, versatility, and accessibility. As developers and end users push for higher sensitivity and ...

WALTHAM, Mass.--(BUSINESS WIRE)--To support the quality of beverage products, Thermo Fisher Scientific today introduced the Thermo Scientific™ SureTect™ Beverage Spoilage Multiplex qPCR Assay**, an ...

A recently declassified document from nearly 50 years ago provides an important piece of the puzzle for open-source researchers seeking to understand the murky origins of the International Atomic ...

The nitrification and urease inhibitors market, valued at USD 3.7 billion in 2025 and projected to reach USD 6.1 billion by 2035, is growing at a CAGR of 5.2%, creating an absolute dollar opportunity ...

An international research team led by the University of Waterloo is developing technology to dissolve painful kidney stones in the urinary tract using tiny robots. The research is published in the ...

Please provide your email address to receive an email when new articles are posted on . A novel assay may help direct antibody-drug conjugate therapy through measurements of HER2 and TROP2. Most ...

Biomarker testing identifies high-risk early-stage NSCLC patients for adjuvant chemotherapy, reducing recurrence risk by 78%. The AIM-HIGH study shows a 96% disease-free survival rate at 24 months ...